Supriya Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 4.64 Cr
- Company Age 39 Year, 6 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 3.00 Cr
- Satisfied Charges ₹ 4.94 Cr
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 6.92%
About Supriya Pharmaceuticals
Supriya Pharmaceuticals Limited (SPL) is a Public Limited Indian Non-Government Company incorporated in India on 24 July 1985 and has a history of 39 years and six months. Its registered office is in Alwar, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.64 Cr.
The company currently has active open charges totaling ₹3.00 Cr. The company has closed loans amounting to ₹4.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramesh Dugar, Manish Gupta, and Yogesh Kumar serve as directors at the Company.
Company Details
-
Location
Alwar, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U01100RJ1985PLC003363
-
Company No.
003363
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
24 Jul 1985
-
Date of AGM
19 Aug 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Supriya Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Dugar
|
Nominee Director | 08-Feb-2012 | Current |
|
Manish Gupta
|
Nominee Director | 06-Feb-2024 | Current |
|
Yogesh Kumar
|
Nominee Director | 16-May-2017 | Current |
Financial Performance of Supriya Pharmaceuticals.
Supriya Pharmaceuticals Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Supriya Pharmaceuticals?
In 2019, Supriya Pharmaceuticals had a promoter holding of 35.36% and a public holding of 64.64%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Dakesh Builders Pvt LtdRamesh Dugar is a mutual person
-
Tarini Overseas Private Limited
Ramesh Dugar is a mutual person
-
R Net Intelligence Systems Private Limited
Ramesh Dugar is a mutual person
-
We Listen Therapies Private Limited
Ramesh Dugar is a mutual person
-
Samriddhi Mega Structures Limited
Ramesh Dugar is a mutual person
-
Trancelogics Private Limited
Ramesh Dugar and Yogesh Kumar are mutual person
Charges (Loans)
₹3.00 Cr
₹4.94 Cr
Charges Breakdown by Lending Institutions
- United Bank Of India : 3.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Aug 2005 | United Bank Of India | ₹3.00 Cr | Open |
| 21 Jan 1998 | Canara Bank | ₹0.30 M | Satisfied |
| 20 Aug 1992 | Canara Bank | ₹3.00 Cr | Satisfied |
| 31 Jan 1992 | Canara Bank | ₹3.00 M | Satisfied |
| 16 Aug 1991 | Canara Bank | ₹5.50 M | Satisfied |
How Many Employees Work at Supriya Pharmaceuticals?
Unlock and access historical data on people associated with Supriya Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Supriya Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supriya Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
